ORCID as entered in ROS

Select Publications
2023, 'Radiological Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: A Review', Journal of Medical Systems, 47, http://dx.doi.org/10.1007/s10916-023-01968-7
,2023, 'Barriers to palliative care in hepatocellular carcinoma: A review of the literature', Journal of Gastroenterology and Hepatology (Australia), 38, pp. 1047 - 1055, http://dx.doi.org/10.1111/jgh.16107
,2023, 'Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort', Digestive Diseases and Sciences, 68, pp. 291 - 303, http://dx.doi.org/10.1007/s10620-022-07483-y
,2023, 'Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions', Gut Microbes, 15, http://dx.doi.org/10.1080/19490976.2023.2240031
,2022, 'Critical Assessment of Whole Genome and Viral Enrichment Shotgun Metagenome on the Characterization of Stool Total Virome in Hepatocellular Carcinoma Patients', Viruses, 15, http://dx.doi.org/10.3390/v15010053
,2022, 'A Tale of Two Fibers: A Liver Twist!', Gastroenterology, 163, pp. 1495 - 1497, http://dx.doi.org/10.1053/j.gastro.2022.09.012
,2022, 'Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up', BMC Gastroenterology, 22, http://dx.doi.org/10.1186/s12876-022-02416-5
,2022, 'Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus', Hepatology Communications, 6, pp. 3260 - 3271, http://dx.doi.org/10.1002/hep4.2089
,2022, 'Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study', Journal of Gastroenterology and Hepatology (Australia), 37, pp. 2173 - 2181, http://dx.doi.org/10.1111/jgh.15986
,2022, 'Virtual clinic for positive faecal occult blood tests enhances early access to bowel cancer screening and is well received by patients', Internal Medicine Journal, 52, pp. 1525 - 1530, http://dx.doi.org/10.1111/imj.15446
,2022, 'Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma', Cancers, 14, http://dx.doi.org/10.3390/cancers14092099
,2022, 'Refining a Protocol for Faecal Microbiota Engraftment in Animal Models After Successful Antibiotic-Induced Gut Decontamination', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.770017
,2022, 'Gastroenterology hospital outpatients report high rates of satisfaction with a Telehealth model of care', Journal of Gastroenterology and Hepatology (Australia), 37, pp. 63 - 68, http://dx.doi.org/10.1111/jgh.15663
,2021, 'Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 −/− mouse model', BMC Microbiology, 21, http://dx.doi.org/10.1186/s12866-021-02171-9
,2021, 'Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-020-20422-7
,2021, 'The case for simplifying and using absolute targets for viral hepatitis elimination goals', Journal of Viral Hepatitis, 28, pp. 12 - 19, http://dx.doi.org/10.1111/jvh.13412
,2020, 'The Use of Image-Guided Navigation Systems During Spine Surgeries in Saudi Arabia: A Cross-Sectional Study', INTERNATIONAL JOURNAL OF SPINE SURGERY, 14, pp. 1016 - 1022, http://dx.doi.org/10.14444/7152
,2020, 'Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management', Internal Medicine Journal, 50, pp. 1038 - 1047, http://dx.doi.org/10.1111/imj.14709
,2020, 'Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma', NEW ENGLAND JOURNAL OF MEDICINE, 382, pp. 1894 - 1905, http://dx.doi.org/10.1056/NEJMoa1915745
,2019, 'Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels', Alimentary Pharmacology and Therapeutics, 49, pp. 1314 - 1322, http://dx.doi.org/10.1111/apt.15248
,2019, 'Chemokine-Regulated Recruitment of Antigen-Specific T-Cell Subpopulations to the Liver in Acute and Chronic Hepatitis C Infection', Journal of Infectious Diseases, 219, pp. 1430 - 1438, http://dx.doi.org/10.1093/infdis/jiy679
,2019, 'Medical complications of homelessness: a neglected side of men’s health', Internal Medicine Journal, 49, pp. 455 - 460, http://dx.doi.org/10.1111/imj.14139
,2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013
,2018, 'Insights into the management of chronic hepatitis C in primary care using MedicineInsight', Australian journal of general practice, 47, pp. 639 - 645, http://dx.doi.org/10.31128/AJGP-02-18-4482
,2018, 'Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy', Journal of Clinical Nursing, 27, pp. 2673 - 2683, http://dx.doi.org/10.1111/jocn.14367
,2018, 'Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study', Journal of Viral Hepatitis, 25, pp. 457 - 464, http://dx.doi.org/10.1111/jvh.12801
,2018, 'Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy', Clinical Gastroenterology and Hepatology, 16, pp. 268 - 277, http://dx.doi.org/10.1016/j.cgh.2017.09.063
,2018, 'Factors associated with non-adherence to HBV antiviral therapy', Antiviral Therapy, 23, pp. 425 - 433, http://dx.doi.org/10.3851/IMP3219
,2018, 'General practitioners require more support to prescribe direct acting antiviral therapy for hepatitis C', Internal Medicine Journal, 48, pp. 105 - 106, http://dx.doi.org/10.1111/imj.13662
,2018, 'Mo1458 - Response to Mycphenolate Mofetil in Patents with Autoimmune Hepatitis who Fail Standard Therapy is Predicted by Serum Gammaglobulin Levels but not Cirrhosis', Gastroenterology, 154, pp. S - 1213, http://dx.doi.org/10.1016/s0016-5085(18)34006-x
,2017, 'Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse', Gastrointestinal Endoscopy, 86, pp. 1070 - 1078, http://dx.doi.org/10.1016/j.gie.2017.09.011
,2017, 'Factors associated with medication adherence in patients living with cirrhosis (vol 25, pg 204, 2016)', JOURNAL OF CLINICAL NURSING, 26, pp. 3751 - 3751, http://dx.doi.org/10.1111/jocn.14074
,2017, 'Adherence to Hepatitis B antiviral therapy: A qualitative study', Gastroenterology Nursing, 40, pp. 239 - 246, http://dx.doi.org/10.1097/SGA.0000000000000161
,2017, 'Factors associated with HBV virological breakthrough', Antiviral Therapy, 22, pp. 53 - 60, http://dx.doi.org/10.3851/IMP3087
,2017, 'Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study', Antiviral Therapy, 22, pp. 699 - 710, http://dx.doi.org/10.3851/IMP3168
,2017, 'Soluble CD147 has an altered expression profile with liver disease progression and in different ethnicities', JOURNAL OF HEPATOLOGY, 66, pp. S658 - S658, http://dx.doi.org/10.1016/S0168-8278(17)31783-X
,2017, 'P13 Call: community assessment and liver liaison, a liver clinic provided to homeless men in their community', Journal of Virus Eradication, 3, pp. 16 - 17, http://dx.doi.org/10.1016/s2055-6640(20)30754-8
,2016, 'Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection', Journal of Viral Hepatitis, 23, pp. 985 - 993, http://dx.doi.org/10.1111/jvh.12576
,2016, 'Elevated serum ferritin: Identifying iron overload', Medicine Today, 7, pp. 51 - 52
,2015, 'Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study', Journal of Diabetes, 7, pp. 809 - 819, http://dx.doi.org/10.1111/1753-0407.12237
,2015, 'Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL II)', ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 42, pp. 829 - 844, http://dx.doi.org/10.1111/apt.13342
,2015, 'Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial', LANCET ONCOLOGY, 16, pp. 859 - 870, http://dx.doi.org/10.1016/S1470-2045(15)00050-9
,2015, 'Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity', Diabetes Research and Clinical Practice, 108, pp. 466 - 472, http://dx.doi.org/10.1016/j.diabres.2015.02.024
,2015, 'HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths', MEDICAL JOURNAL OF AUSTRALIA, 202, pp. VI - VI, http://dx.doi.org/10.5694/mja15.00165
,2014, 'A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection', Journal of Hepatology, 61, pp. 1238 - 1246, http://dx.doi.org/10.1016/j.jhep.2014.07.022
,2014, 'Obese visceral adipose tissue exhibits altered T cell trafficking patterns and confers a unique phenotype to tissue-resident T cells', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 23 - 23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343863000048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Historical epidemiology of hepatitis C virus (HCV) in selected countries', Journal of viral hepatitis, 21, pp. 5 - 33, http://dx.doi.org/10.1111/jvh.12247
,2014, 'Strategies to manage hepatitis C virus (HCV) disease burden', Journal of viral hepatitis, 21, pp. 60 - 89, http://dx.doi.org/10.1111/jvh.12249
,2014, 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', Journal of viral hepatitis, 21, pp. 34 - 59, http://dx.doi.org/10.1111/jvh.12248
,2014, 'Characterization of the cytokine milieu associated with the upregulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders', Liver International, http://dx.doi.org/10.1111/liv.12473
,